NeoRx Avicidin is latest addition in growing Janssen oncology pipeline.
Executive Summary
NEORx AVICIDIN IS NEWEST ADDITION TO JANSSEN ONCOLOGY RESEARCH PORTFOLIO through an alliance valued at up to $60 mil., the companies announced Aug. 12. Janssen will acquire a worldwide exclusive license to market the monoclonal antibodies product for treatment of solid tumors in the lung, colon, breast and prostate. Avicidin is in Phase I/II trials.